IL-STATS-PERFORM
7.10.2019 13:02:09 CEST | Business Wire | Press release
Today, Stats Perform , the revolutionary leader in sports AI and data, and Control Risks , the leading specialist risk consultancy, announce a unique partnership to bring best-in-class comprehensive sports integrity solutions to the market.
Through Stats Perform’s Integrity Unit, sports industry stakeholders such as rights holders, International Federations and Governing Bodies will be able to access Control Risks’ global investigative capabilities to help drive out corruption and match-fixing. Integrity units and compliance departments will have access to a full range of solutions, including forensic accounting, data analytics and traditional investigative capabilities, to manage risk or conduct investigations.
The partnership will combine Stats Perform’s offering across prevention, detection and investigation with Control Risks’ global investigative practice and experience in building resilient and compliant governance programmes. Together, they will help stakeholders ensure their integrity, anti-doping and compliance programmes are fit-for-purpose, while protecting the long-term value of their brands.
Furthermore, global sport stakeholders will be able to utilise the full suite of services the partnership has to offer, whether it is a team requiring due diligence on a potential investor, sponsor or new signing, or a business looking to partner with a new league or competition. The partnership will enable sports stakeholders to manage both sporting integrity and business risks in one place.
Nick Allan , CEO of Control Risks, said: “We are delighted to announce this exciting new partnership with Stats Perform to help the sports industry in its desire to combat the threats to its integrity posed by corruption and match-fixing. Our global investigations capabilities will enable all stakeholders, to be able to call on our support as part of their contract with Stats Perform.”
Mike Perez , COO of Stats Perform, said: “As the sports industry goes through a data revolution, our existing integrity services will benefit from complementary investigative capabilities to identify, investigate and respond to threats. We are very pleased to move forward with Control Risks who have the global capabilities to match our aspirations.”
Jonny Gray , Global Head of Sport at Control Risks, said: “This is a very exciting development as the sports industry looks for comprehensive support to combat existential threats to its integrity, trust and value. It gives Stats Perform’s clients the opportunity for a complete integrity solution.”
Jake Marsh , Head of Integrity at Stats Perform, said: “Sports stakeholders face a variety of governance and integrity challenges. Our role is not simply to help them identify and mitigate risk, but to assist in investigation and response. Our partnership with Control Risks helps us do that and provide a better, more complete service to our clients.”
About Control Risks
Control Risks is a specialist risk consulting firm that helps create secure, compliant and resilient organizations. We believe that taking risks is essential to success, so we provide the insight and intelligence you need to realize opportunities and grow.
Our experts across 34 offices bring experience in prosecution and law enforcement, accounting, management consulting, regional business intelligence, forensic technology and cyber security to advise the world’s largest multinational companies on major regulatory issues, conduct complex cross-border investigations and build robust compliance programs.
Learn more at www.controlrisk.com/sport
About Stats Perform
Stats Perform collects the richest sports data in the world and transforms it through revolutionary artificial intelligence (AI) to unlock the most in-depth insights for media and technology, betting and team performance. With company roots dating back almost 40 years, Stats Perform embraces and solves the dynamic nature of sport – be that for digital and broadcast media with differentiated storytelling, tech companies with reliable and fast data to power their innovations, sportsbooks with in-play betting and integrity services, or teams with first-of-its-kind AI analysis software. As the leading sports data and AI company, Stats Perform works with the top global sports media, tech companies, sportsbooks, teams and leagues.
For more information, visit StatsPerform.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20191007005277/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom